Acuta Capital Partners
Acuta Capital Partners reported 34 stocks worth $130M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PRAX (18.9%), WHWK (13.6%) and TNGX (7.9%). Compared with Q2 2026, the fund opened new positions in VOGX, SLN and IRD, added to PRAX, TNGX and FDMT and trimmed AVBP, SRZN and AVLN.
Latest filing: what Acuta Capital Partners did in Q3 2026
vs Q2 2026None
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() PRAX Praxis Precision Medicines I | $24.5M | 18.9% | 84K | +1,397 (+2%) | 8 of 8 | |
| 2 | ![]() WHWK Whitehawk Therapeutics Inc | $17.6M | 13.6% | 4.7M | No change | 8 of 8 | |
| 3 | ![]() TNGX Tango Therapeutics Inc | $10.2M | 7.9% | 410K | +19K (+5%) | 4 of 8 | |
| 4 | ![]() FDMT 4D Molecular Therapeutics in | $7.7M | 5.9% | 535K | +27K (+5%) | 2 of 8 | |
| 5 | ![]() ARGX Argenx SE | $5.3M | 4.1% | 5,558 | +853 (+18%) | 8 of 8 | |
| 6 | ![]() AVBP Arrivent Biopharma Inc | $5.2M | 4.0% | 171K | −48K (−22%) | 2 of 8 | |
| 7 | ![]() SRZN Surrozen Inc | $4.9M | 3.8% | 153K | −21K (−12%) | 7 of 8 | |
| 8 | ![]() VOGX Vogenx Inc | $4.9M | 3.8% | 213K | New position | 1 of 8 | |
| 9 | ![]() DRUG Bright Minds Biosciences Inc | $4.6M | 3.6% | 93K | +407 (+0%) | 8 of 8 | |
| 10 | ![]() OCUL Ocular Therapeutix Inc | $4.4M | 3.4% | 575K | +42K (+8%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() ACAD Acadia Pharmaceuticals Inc | Call | $2M | 1,000 | +1,000 |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Acuta Capital Partners 13F FAQ
What does Acuta Capital Partners own?
Acuta Capital Partners reported 34 stocks worth $130M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PRAX (18.9%), WHWK (13.6%) and TNGX (7.9%). The table above lists every position in the filing (the top 10 without an account).
What did Acuta Capital Partners buy and sell in Q3 2026?
Compared with Q2 2026: 11 new positions, 12 added to, 8 trimmed and 0 sold out. New positions include VOGX, SLN and IRD.
When will Acuta Capital Partners file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Acuta Capital Partners's portfolio worth?
The Q3 2026 filing reports $130M in US stocks ($132M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.




















